kabutan

TMS Co., Ltd.(4891) Summary

4891
TSE Growth
TMS Co., Ltd.
147
JPY
-3
(-2.00%)
Mar 13, 3:30 pm JST
0.92
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
2.44
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
146 JPY 0.91 USD
Previous Close Mar 12
150 JPY 0.94 USD
High Mar 13, 9:08 am
148 JPY 0.93 USD
Low Mar 13, 9:58 am
144 JPY 0.90 USD
Volume
181,300
Trading Value
0.03B JPY 0.17M USD
VWAP
146.13 JPY 0.92 USD
Minimum Trading Value
14,700 JPY 92 USD
Market Cap
6.69B JPY 0.04B USD
Number of Trades
93
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Mid
1-Year Average
247
1-Year High Jul 18, 2025
1,749
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 3,825,700
Feb 27, 2026 0 3,643,100
Feb 20, 2026 0 3,732,600
Feb 13, 2026 0 3,558,100
Feb 6, 2026 0 3,592,400
Company Profile
TMS Co., Ltd. is a drug discovery bioventure originating from Tokyo University of Agriculture and Technology. The company has partnered with US-based Biogen for its acute ischemic stroke drug candidate.
Sector
Pharmaceuticals
TMS Co., Ltd., a drug discovery bioventure spun off from Tokyo University of Agriculture and Technology, focuses its business on developing TMS-007, a drug candidate for acute ischemic stroke. TMS-007 possesses both thrombolytic and anti-inflammatory properties and has shown promising results in Phase IIa clinical trials. The company has partnered with Hong Kong-based JIXING and retains development and marketing rights for Japan. TMS Co., Ltd. also has multiple pipelines, including TMS-008 for acute kidney injury and cancer cachexia, and JX09, a candidate for hypertension treatment. The company's growth strategy involves in-licensing and developing drug seeds from academia through collaborative research with universities and other institutions, aiming to expand into the global market.